BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12681992)

  • 1. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
    Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
    Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
    Galimberti S; Papineschi F; Carmignani A; Testi R; Fazzi R; Petrini M
    Bone Marrow Transplant; 1999 Aug; 24(3):345-8. PubMed ID: 10455379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
    Lu Q; Chen Y; Li Z
    Leuk Res; 2012 Jun; 36(6):e119-21. PubMed ID: 22386731
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
    Lin J; Zhu H; Li S; Fan H; Lu X
    Ann Hematol; 2014 Feb; 93(2):335-6. PubMed ID: 23719691
    [No Abstract]   [Full Text] [Related]  

  • 10. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
    Tallman MS; Manji GA
    Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
    [No Abstract]   [Full Text] [Related]  

  • 11. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L
    Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
    George B; Poonkuzhali B; Srivastava VM; Chandy M; Srivastava A
    Ann Hematol; 2005 Jun; 84(6):406-8. PubMed ID: 15592671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Zhang X; Pan J
    Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
    Au WY; Chim CS; Wai Lie AK; Pang A; Kwong YL
    Haematologica; 2002 Oct; 87(10):1109-11. PubMed ID: 12368167
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
    Au WY; Chim CS; Lie AK; Liang R; Kwong YL
    Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
    Inoue A; Kawakami C; Takitani K; Tamai H
    Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.